Published in J Acquir Immune Defic Syndr on July 01, 2010
Developments in CD4 and viral load monitoring in resource-limited settings. Clin Infect Dis (2013) 2.09
CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectiveness study. BMJ (2011) 1.96
Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models. Lancet Glob Health (2013) 1.96
Cost-effectiveness of point-of-care viral load monitoring of antiretroviral therapy in resource-limited settings: mathematical modelling study. AIDS (2013) 1.88
Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir Ther (2012) 1.71
Sustainable HIV treatment in Africa through viral-load-informed differentiated care. Nature (2015) 1.67
Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe. PLoS One (2012) 1.33
Cost analysis of centralized viral load testing for antiretroviral therapy monitoring in Nicaragua, a low-HIV prevalence, low-resource setting. J Int AIDS Soc (2010) 1.28
The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa. Clin Infect Dis (2012) 1.21
HIV treatment and care in resource-constrained environments: challenges for the next decade. J Int AIDS Soc (2012) 1.21
Switching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non-inferiority trial in Thailand. PLoS Med (2013) 1.20
Monitoring of antiretroviral therapy and mortality in HIV programmes in Malawi, South Africa and Zambia: mathematical modelling study. PLoS One (2013) 1.11
Could early antiretroviral therapy entail more risks than benefits in sub-Saharan African HIV-infected adults? A model-based analysis. Antivir Ther (2012) 0.92
The cost-effectiveness of monitoring strategies for antiretroviral therapy of HIV infected patients in resource-limited settings: software tool. PLoS One (2015) 0.89
Treatment switching in South Indian patients on HAART: what are the predictors and consequences? AIDS Care (2011) 0.88
Regional differences in predictive accuracy of WHO immunologic failure criteria. AIDS (2012) 0.86
Antiretroviral therapy in Indian setting: when & what to start with, when & what to switch to? Indian J Med Res (2011) 0.84
Lives saved by expanding HIV treatment availability in resource-limited settings: the example of Haiti. J Acquir Immune Defic Syndr (2013) 0.83
Cost-effectiveness of HIV drug resistance testing to inform switching to second line antiretroviral therapy in low income settings. PLoS One (2014) 0.80
Patient- and population-level health consequences of discontinuing antiretroviral therapy in settings with inadequate HIV treatment availability. Cost Eff Resour Alloc (2012) 0.79
Modeling the cost-effectiveness of HIV treatment: how to buy the most 'health' when resources are limited. Curr Opin HIV AIDS (2013) 0.79
Clinical impact and cost-effectiveness of making third-line antiretroviral therapy available in sub-Saharan Africa: a model-based analysis in Côte d'Ivoire. J Acquir Immune Defic Syndr (2014) 0.77
Initiation of antiretroviral therapy. Indian J Sex Transm Dis (2014) 0.76
Pretreatment HIV-1 drug resistance is strongly associated with virologic failure in HIV-infected patients receiving partly active antiretroviral regimens. Future Microbiol (2012) 0.75
A simple Phosphate Buffered Saline extraction method improves specificity of HIV viral load monitoring using dried blood spots. J Clin Microbiol (2017) 0.75
Predictors of treatment failure on second-line antiretroviral therapy among adults in northwest Ethiopia: a multicentre retrospective follow-up study. BMJ Open (2016) 0.75
Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies. Clin Infect Dis (2016) 0.75
CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med (2006) 22.76
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med (1997) 16.44
Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA (1996) 14.23
Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA (1996) 8.52
The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA (1996) 6.80
Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet (1999) 6.40
Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol (2003) 5.81
Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. N Engl J Med (2006) 5.62
Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet (2003) 5.17
Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis (2008) 5.14
HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis (2006) 4.56
Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS (2009) 4.54
Rapid scaling-up of antiretroviral therapy in 10,000 adults in Côte d'Ivoire: 2-year outcomes and determinants. AIDS (2008) 4.40
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS (2005) 4.07
Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis. Arch Intern Med (2008) 2.96
Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis (2008) 2.96
Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. AIDS (2008) 2.84
Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Côte d'Ivoire. Antivir Ther (2003) 2.40
Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis. AIDS (2005) 2.39
Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis (2000) 2.36
CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr (2008) 2.32
Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS (2008) 2.25
The cost effectiveness of antiretroviral treatment strategies in resource-limited settings. AIDS (2007) 1.89
The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte d'Ivoire. Antivir Ther (2007) 1.68
Tolerance and acceptability of an efavirenz-based regimen in 740 adults (predominantly women) in West Africa. J Acquir Immune Defic Syndr (2006) 1.66
Progression to WHO criteria for antiretroviral therapy in a 7-year cohort of adult HIV-1 seroconverters in Abidjan, Côte d'Ivoire. Bull World Health Organ (2007) 1.48
Viral load testing in resource-limited settings. Clin Infect Dis (2006) 1.47
African regional external quality assessment for CD4 T-cell enumeration: development, outcomes, and performance of laboratories. Cytometry B Clin Cytom (2008) 1.45
Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. AIDS (2007) 1.34
The impact of monitoring HIV patients prior to treatment in resource-poor settings: insights from mathematical modelling. PLoS Med (2008) 1.32
Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world. J Acquir Immune Defic Syndr (2007) 1.32
HIV drug resistance surveillance for prioritizing treatment in resource-limited settings. AIDS (2007) 1.30
Preventing and managing antiretroviral drug resistance. AIDS Patient Care STDS (2004) 1.22
Morbidity before and after HAART initiation in Sub-Saharan African HIV-infected adults: a recurrent event analysis. AIDS Res Hum Retroviruses (2007) 1.15
Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study. AIDS (2008) 1.11
Monitoring of antiretroviral therapy in low-resource settings. Lancet (2008) 1.11
Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200-500 CD4 cells/mm(3) (ACTG 175). AIDS Clinical Trials Group Protocol 175 Team. J Infect Dis (1998) 1.04
Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failure. J Acquir Immune Defic Syndr (2006) 1.01
Monitoring of antiretroviral therapy in low-resource settings. Lancet (2008) 0.98
The cost-effectiveness of antiretroviral therapy for treating HIV disease in the Caribbean. J Acquir Immune Defic Syndr (2007) 0.98
Variability in repeated consecutive measurements of plasma human immunodeficiency virus RNA in persons receiving stable nucleoside reverse transcriptase inhibitor therapy or no treatment. J Infect Dis (1998) 0.97
Monitoring antiretroviral failure in resource-poor settings. Lancet (2008) 0.90
Monitoring of antiretroviral therapy in low-resource settings. Lancet (2008) 0.78
Global health 2035: a world converging within a generation. Lancet (2013) 16.85
Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS (2008) 13.25
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ (2008) 8.70
Expanded screening for HIV in the United States--an analysis of cost-effectiveness. N Engl J Med (2005) 8.49
Long-term persistence in use of statin therapy in elderly patients. JAMA (2002) 7.19
The survival benefits of AIDS treatment in the United States. J Infect Dis (2006) 7.08
Surgery versus physical therapy for a meniscal tear and osteoarthritis. N Engl J Med (2013) 6.08
The lifetime cost of current human immunodeficiency virus care in the United States. Med Care (2006) 5.87
Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. N Engl J Med (2006) 5.62
Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med (2006) 5.53
Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr (2009) 5.40
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med (2015) 5.30
Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis (2008) 5.14
Does preventive care save money? Health economics and the presidential candidates. N Engl J Med (2008) 4.78
The "ART" of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa. PLoS One (2010) 4.75
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med (2013) 4.43
Association between hospital and surgeon procedure volume and the outcomes of total knee replacement. J Bone Joint Surg Am (2004) 4.42
Rapid scaling-up of antiretroviral therapy in 10,000 adults in Côte d'Ivoire: 2-year outcomes and determinants. AIDS (2008) 4.40
Rates and outcomes of primary and revision total hip replacement in the United States medicare population. J Bone Joint Surg Am (2003) 4.38
When to start antiretroviral therapy in resource-limited settings. Ann Intern Med (2009) 4.31
Medicare and cost-effectiveness analysis. N Engl J Med (2005) 4.20
Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol (2004) 4.20
Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ (2009) 4.18
CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet (2006) 4.06
Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis (2010) 3.96
Who starts antiretroviral therapy in Durban, South Africa?... not everyone who should. AIDS (2010) 3.93
Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan. Am J Respir Crit Care Med (2005) 3.90
HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis (2009) 3.89
Cost-effectiveness of total knee arthroplasty in the United States: patient risk and hospital volume. Arch Intern Med (2009) 3.84
Health and economic implications of HPV vaccination in the United States. N Engl J Med (2008) 3.81
Introducing HPV vaccine in developing countries--key challenges and issues. N Engl J Med (2007) 3.77
Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS (2007) 3.70
Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet (2006) 3.60
Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. N Engl J Med (2014) 3.57
Mortality of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa: comparison with HIV-unrelated mortality. PLoS Med (2009) 3.42
CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr (2006) 3.39
Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J Clin Microbiol (2005) 3.36
Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst (2008) 3.33
Incidence rates of dislocation, pulmonary embolism, and deep infection during the first six months after elective total hip replacement. J Bone Joint Surg Am (2003) 3.33
Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis (2009) 3.30
Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA (2003) 3.25
Alcohol consumption and antiretroviral adherence among HIV-infected persons with alcohol problems. Alcohol Clin Exp Res (2004) 3.24
Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst (2004) 3.11
Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2013) 3.10
Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol (2002) 3.09
Early infant HIV-1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more cost-effective interventions. BMC Med (2011) 3.08
Association of hospital and surgeon volume of total hip replacement with functional status and satisfaction three years following surgery. Arthritis Rheum (2003) 2.98
Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis (2008) 2.96
Screening for Chlamydia trachomatis in women 15 to 29 years of age: a cost-effectiveness analysis. Ann Intern Med (2004) 2.95
Routine voluntary HIV testing in Durban, South Africa: the experience from an outpatient department. J Acquir Immune Defic Syndr (2007) 2.91
Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol (2011) 2.83
American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin (2007) 2.81
Correcting mortality for loss to follow-up: a nomogram applied to antiretroviral treatment programmes in sub-Saharan Africa. PLoS Med (2011) 2.80
HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2004) 2.78